Obstructive Sleep ApneaPhase 1/2NCT05558501
Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities
A Phase 1/2 study testing Mild Intermittent Hypoxia in people with Obstructive Sleep Apnea, run by VA Office of Research and Development at 1 site in United States.
Trial summary
The prevalence of obstructive sleep apnea (OSA) is high in the United States and is a major health concern. This disorder is linked to numerous heart, blood vessel and nervous system abnormalities, along with increased tiredness while performing exercise likely because of a reduced blood supply to skeletal muscles. Read more about this study
- Who is it for?
- Ages 30 to 60 years
- Conditions the study is for
- Obstructive Sleep Apnea
- What is being tested?
- Mild Intermittent Hypoxia
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 60 participants
- Where
- 1 siteUnited States
- Study dates
- 1 Jan 2023to 31 Dec 2027
- Phase
- Phase 1/2
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 30 to 60 years
- All sexes
- No healthy volunteers
- Adult
Who may be able to join
- Male or female of any race, 30-60 years of age with a BMI of less than 40 kg/m2 and a weight to hip ratio of less than 1.3in males and 1.2 in females along with pure or predominantly (i.e., comprised of both a central and obstructive component)OSA (AHI less than or equal to 100 events per hour and an average oxygen desaturation level of 85 % or greater).
- Participants will be newly diagnosed and not previously treated with CPAP.
- Participants will also be diagnosed with hypertension. Participants will either be untreated or will be treated unsuccessfully with a single prescribed medication for hypertension. Hypertension will be classified according to the American Heart Association 2018 criteria which includes an elevated systolic blood pressure in the range of 120-129 and a diastolic pressure less than 80 mmHg in addition to stage I and stage II hypertension defined by a systolic blood pressure greater than 130 mmHg and a diastolic pressure greater than 80 mmHg.
- Participants will also be included if they are pre-diabetic (HbA1C: 5.7 - 6.4 %; fasting blood glucose: 100 - 125 mg/dL) and have cholesterol levels ranging from 200-239 mg/dL.
- All participants will have normal lung function and a normal EKG with no or minimal alcohol consumption (< 2 oz of alcohol/night).
- Females will be studied at similar points in their menstrual cycle.
Who cannot join
- Participants with baseline blood pressure greater than 160/110 will be excluded from participation.
- Participants on any medications, with the exception of a single prescribed medication for individuals with resistant hypertension.
- Participants with any other known disease (e.g. pulmonary hypertension).
- Participants using any sleep promoting supplements including melatonin.
- Night shift workers or participants who recently travelled across time zones.
- Pregnant females.
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
United States1 site, 1 recruiting
- Recruiting
John D. Dingell VA Medical Center, Detroit, MI
Detroit, Michigan, 48201-1916
Edi Levi, MD, 313-576-4451, edi.levi@va.gov
Erin Olgren, PhD MS, (313) 576-4448, erin.olgren@va.gov
About this study
The prevalence of obstructive sleep apnea (OSA) is high in the United States and is a major health concern. This disorder is linked to numerous heart, blood vessel and nervous system abnormalities, along with increased tiredness while performing exercise likely because of a reduced blood supply to skeletal muscles. The gold standard treatment of OSA with continuous positive airway pressure (CPAP) in many cases does not lead to significant improvements in health outcomes because the recommended number of hours of treatment per night is often not achieved. Thus, development of novel treatments to eliminate apnea and lessen the occurrence of associated health conditions is important. The investigators will address this mandate by determining if repeated exposure to mild intermittent hypoxia (MIH) reduces heart and blood vessel dysfunction and tiredness/ fatigue experienced while exercise performance. The investigators propose that exposure to MIH has a multipart effect. MIH directly targets heart and blood vessel associated conditions, while simultaneously increasing upper airway stability and improving sleep quality. These modifications may serve to directly decrease breathing episodes and may also serve to improve usage of CPAP. Independent of its effect, MIH may serve as an adjunctive therapy which provides another path to reducing heart and blood vessel abnormalities that might ultimately result in improvements in exercise capacity and reverse performance fatigue in individuals with OSA.
Read the detailed description
The prevalence of obstructive sleep apnea (OSA) is high in the Veteran population and this disorder is linked to numerous cardiovascular, neurocognitive and metabolic abnormalities. Thus, OSA is a major health concern in the Veteran population. Treatment of OSA in many cases does not lead to significant improvements in outcome measures. This inadequacy may be a consequence of reduced treatment adherence with continuous positive airway pressure (CPAP) or because the effect of CPAP on outcome measures is small or absent in some patients despite adequate adherence. Consequently, innovative therapies that directly impact co-morbidities linked to OSA or that increase CPAP adherence could lead to improved outcome measures. In the recent funding cycle, the investigators established that repeated daily exposure to mild intermittent hypoxia (MIH) coupled with CPAP modifies autonomic nervous system activity and dramatically decreases blood pressure compared to CPAP treatment alone. Because MIH was coupled with CPAP, the independent effect of MIH on blood pressure was not established. Moreover, it was not established if these outcomes were sustained for a prolonged time period (i.e. weeks to months).
Although the investigators obtained some indirect evidence that modifications in autonomic nervous system activity were coupled to the reduction in blood pressure, the investigators did not establish if modifications in microvascular function were evident. Microvascular dysfunction together with sympatho-vagal imbalance may have consequences not only for peripheral vascular resistance and blood pressure but also for muscle perfusion and metabolism, thereby limiting exercise performance and increasing fatigability in patients with OSA. Thus, reductions in blood pressure and improvement in microvascular function following treatment with MIH might serve to improve exercise capacity and reverse performance fatigue in individuals with OSA.
Besides its potential effect on autonomic and cardiovascular function, the investigators and others previously established that acute exposure to MIH initiates sustained increases in upper airway muscle activity in humans. This sustained increase is a form of respiratory plasticity known as long-term facilitation. However, in the absence of CPAP the investigators have shown that acute MIH immediately prior to or during sleep leads to increases in apnea severity. This might occur because the manifestation of long-term facilitation is absent in the presence of hypocapnia. Hypocapnia can be induced during sleep by the initiation of another form of plasticity known as progressive augmentation. However, it is possible that the combination of daily exposure to MIH administered many hours before the sleep period may mitigate the effects of progressive augmentation leading to increased upper airway stability.
Independent of this possibility, the investigators showed in the previous funding cycle that increased upper airway stability following treatment with MIH was coupled to a reduction in therapeutic CPAP and improved adherence. However, improved adherence to CPAP might also be linked to an increase in the arousal threshold to both respiratory and non-respiratory stimuli. All the uncertainties outlined above will be addressed in the present proposal.
- Conditions
- Obstructive Sleep Apnea
- Being tested
- Mild Intermittent Hypoxia, Sham MIH
- Keywords
- Intermittent Hypoxia, Microvascular Function, Fatigability, Maximal Oxygen Consumption, Sympatho-Vagal Balance, CPAP Adherence, Arousal Threshold
- Medical subject headings
- Sleep Apnea, Obstructive
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Mild Intermittent HypoxiaOther
The MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia [partial pressure of end-tidal oxygen (PETO2)= 50 mmHg]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide.
Sham MIHOther
During "sham MIH" the participants will be exposed to compressed air (the equivalent of room air).
| Study group | Role | What they receive |
|---|---|---|
| Mild Intermittent Hypoxia (MIH) | Experimental | This arm of the protocol will receive mild intermittent hypoxia (8% oxygen) with end-tidal carbon dioxide maintained 2 millimeters of mercury above baseline, while in the laboratory. Receives: Other: Mild Intermittent Hypoxia |
| Sham Mild Intermittent Hypoxia (Sham MIH) | Sham comparator | This arm of the protocol will receive sham MIH (the equivalent of room air), while in the laboratory. Receives: Other: Sham MIH |
What is being measured
The primary outcome is the main question the study is designed to answer.
Change in Blood Pressure
Blood pressure measures over 24 hours will be obtained. Blood pressure will be measured every 20 minutes beginning on Sunday at 6 AM and ending Monday at 6 AM. Participants will wear an actigraph (Actiwatch Spectrum, Respironics) and record their activities in a journal to determine the arousal state (i.e., active wakefulness, quiet wakefulness and sleep) associated with each blood pressure measurement. The data will be separated into active-awake, rest-awake and sleep based on the activity log and corresponding data from an actigraph watch.
The average value of blood pressure in a healthy individual is 120/80 mmHg. In their participants with OSA, the investigators expect the blood pressure to be higher at baseline and decrease 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.
Measured: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Microvascular Function (Maximal hyperemic Response)
Microvascular reactivity associated with hyperemia induced by vascular occlusion will be determined by analyzing the maximal hyperemic response (MHR) of tissue saturation index (TSI) signal derived from near-infrared spectroscopy (NIRS) of the lateral gastrocnemius muscle of the non-dominant leg.
The average value of TSI MHR of the NIRS signals in healthy individuals is 159±9 %. In their participants with OSA, the investigators expect these values to be lower at baseline and to increase 15 days after treatment. The investigators also expect that the increase will be maintained 4 and 8-weeks following treatment.
Measured: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Microvascular Function (Time to reach Maximal Hyperemic Response)
Microvascular reactivity associated with hyperemia induced by vascular occlusion will be determined by analyzing the time to reach maximal hyperemic response (tM) of tissue saturation index (TSI) signal derived from near-infrared spectroscopy (NIRS) of the lateral gastrocnemius muscle of the non-dominant leg.
The average value of tM TSI in healthy individuals is 39±5 s. In their participants with OSA, the investigators expect these values to be higher at baseline and to lower 15 days after treatment. The investigators also expect that the decrease will be maintained 4 and 8-weeks following treatment.
Measured: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Secondary outcomes (7)
Change in Muscle Oxygen Extraction (Time Delay)
Gastrocnemius muscle deoxygenation will be determined by monitoring temporal variables i.e. time delay of [HHb] signal recorded during the MIH and "sham MIH" treatment. Lying in a supine position, participants will be fitted with the NIRS optode on the belly of the lateral gastrocnemius muscle secured with a double tape or a velcro strap. The NIRS data will be recorded continuously at a sampling rate of 10 Hz and will be analyzed off line.
The average reported value of [HHb] time delay in a healthy individual is 14.8±1.6s. In their participants with OSA, the investigators expect these values to be higher at baseline and decrease 15 days after treatment.
Measured: Change at 15 days following treatment compared to baseline
Change in Muscle Oxygen Extraction (Mean Response Time)
Gastrocnemius muscle deoxygenation will be determined by monitoring temporal variables i.e. mean response time of [HHb] signal recorded during the MIH and "sham MIH" treatment. Lying in a supine position, participants will be fitted with the NIRS optode on the belly of the lateral gastrocnemius muscle secured with a double tape or a velcro strap. The NIRS data will be recorded continuously at a sampling rate of 10 Hz and will be analyzed off line.
The average reported value of [HHb] mean response time in a healthy individual is 27.2±2.9s. In their participants with OSA, the investigators expect these values to be higher at baseline and decrease 15 days after treatment.
Measured: Change at 15 days following treatment compared to baseline
Change in Sympatho-Vagal Balance (Blood Pressure Variability)
Blood pressure variability will be assessed non-invasively using beat to beat measures of blood pressure. The ratio of low frequency and high frequency range (LF-HF ratio) obtained from the power spectrum analysis of blood pressure variability is considered representative of sympathetic to parasympathetic balance in both physiological and pathophysiological conditions.
The normal range of LF-HF ratio in a healthy individual is 1.5-2. In their participants with OSA, the investigators expect the ratio to be higher at baseline and decrease 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.
Measured: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Muscle Oxygen Extraction (Tau)
Gastrocnemius muscle deoxygenation will be determined by monitoring temporal variable i.e. tau of [HHb] signal recorded during the MIH and "sham MIH" treatment. Lying in a supine position, participants will be fitted with the NIRS optode on the belly of the lateral gastrocnemius muscle secured with a double tape or a velcro strap. The NIRS data will be recorded continuously at a sampling rate of 10 Hz and will be analyzed off line.
The average reported value of [HHb] tau in a healthy individual is 12.4±2.2s. In their participants with OSA, the investigators expect these values to be higher at baseline and decrease 15 days after treatment.
Measured: Change at 15 days following treatment compared to baseline
Change in Maximal Oxygen Consumption
All the participants will complete a maximum oxygen consumption (VO2 max) test using a treadmill. Continuous monitoring of electrical activity of the heart with an electrocardiogram along with the measurement of breath by breath oxygen consumption and carbon dioxide production will be performed.
The average value of VO2 max in a healthy individual is 35-40 mL/kg/min. In their participants with OSA, the investigators expect the maximal oxygen consumption to be lower at baseline and increase 15 days after treatment. The investigators also expect that this increase will be maintained at 4 and 8-weeks following treatment.
Measured: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Fatigability
Participants will perform a 10-minute walk test on a 25 m indoor walking course at the beginning and end of the protocol. The distance covered will be recorded every 2.5 minutes and at the end of 10 minutes. The ratio of the average walking speed calculated over the entire 10 minutes of walking and the walking velocity calculated over the first 2.5 minutes of the test will be computed. This ratio will then be normalized to the total distance covered in 10 minutes to calculate the performance fatigability index.
The average value of performance fatigability index in a healthy individual is less than 1. In the participants with OSA, the investigators expect the performance fatigability index to be higher at baseline and reduce 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.
Measured: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Sympatho-Vagal Balance (Heart Rate Variability)
Heart rate variability will be assessed non-invasively using beat to beat measures of heart rate. The ratio of low frequency and high frequency range (LF-HF ratio) obtained from the power spectrum analysis of heart rate variability is considered representative of sympathetic to parasympathetic balance in both physiological and pathophysiological conditions.
The average value of LF-HF ratio in a healthy individual is 1.6±1. In their participants with OSA, the investigators expect the ratio to be higher at baseline and decrease 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.
Measured: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted28 Sep 2022
- Study start1 Jan 2023
- Primary completion31 Dec 2026 (estimated)
- Study completion31 Dec 2027 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Obstructive Sleep ApneaStudies of the same condition, open and under way.
- More trials run by VA Office of Research and DevelopmentThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase 1/2
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Model description
- The present study utilizes a double blind parallel randomized design using an equal allocation ratio for each arm. Block randomization will be conducted to reduce the probability that a disproportionate number of participants are randomized to one group. Mild intermittent hypoxia and "sham MIH" will be administered during wakefulness each day for 15 days over a 3-week period.
- Masking
- Double blind
- Who is masked
- Participant, Outcomes assessor
- Enrolment
- 60 participants (estimated)
Sponsor and investigators
- Lead sponsor
- VA Office of Research and Development
- Sponsor type
- US federal agency
- Collaborators
- John D. Dingell VA Medical Center
- Responsible party
- Sponsor
- Investigators
- Jason H Mateika, PhD MS BS, Principal investigator, John D. Dingell VA Medical Center, Detroit, MI
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT05558501
- Sponsor's protocol ID
- PULM-003-22S
- Other IDs
- CX000125
- Status last verified
- Dec 2025
- First submitted
- 19 Sep 2022
- Last updated
- 4 Dec 2025
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- No
Study at a glance
From the registry record, last updated by the sponsor on 4 Dec 2025. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities
- ClinicalTrials.gov ID
- NCT05558501
- Acronym / sponsor ID
- PULM-003-22S
- Conditions
- Obstructive Sleep Apnea
- Keywords
- Intermittent Hypoxia, Microvascular Function, Fatigability, Maximal Oxygen Consumption, Sympatho-Vagal Balance, CPAP Adherence, Arousal Threshold
- Phase
- Phase 1/2
- Study type
- Interventional
- Recruitment status
- Recruiting
- Enrolment
- 60 participants (estimated)
- Lead sponsor
- VA Office of Research and DevelopmentUS federal agency
- Collaborators
- John D. Dingell VA Medical Center
- Study start
- 1 Jan 2023 (actual)
- Primary completion
- 31 Dec 2026 (estimated)
- Study completion
- 31 Dec 2027 (estimated)
- First posted
- 28 Sep 2022 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The prevalence of obstructive sleep apnea (OSA) is high in the United States and is a major health concern. This disorder is linked to numerous heart, blood vessel and nervous system abnormalities, along with increased tiredness while performing exercise likely because of a reduced blood supply to skeletal muscles. The gold standard treatment of OSA with continuous positive airway pressure (CPAP) in many cases does not lead to significant improvements in health outcomes because the recommended number of hours of treatment per night is often not achieved. Thus, development of novel treatments to eliminate apnea and lessen the occurrence of associated health conditions is important. The investigators will address this mandate by determining if repeated exposure to mild intermittent hypoxia (MIH) reduces heart and blood vessel dysfunction and tiredness/ fatigue experienced while exercise performance. The investigators propose that exposure to MIH has a multipart effect. MIH directly targets heart and blood vessel associated conditions, while simultaneously increasing upper airway stability and improving sleep quality. These modifications may serve to directly decrease breathing episodes and may also serve to improve usage of CPAP. Independent of its effect, MIH may serve as an adjunctive therapy which provides another path to reducing heart and blood vessel abnormalities that might ultimately result in improvements in exercise capacity and reverse performance fatigue in individuals with OSA.
Detailed description
The prevalence of obstructive sleep apnea (OSA) is high in the Veteran population and this disorder is linked to numerous cardiovascular, neurocognitive and metabolic abnormalities. Thus, OSA is a major health concern in the Veteran population. Treatment of OSA in many cases does not lead to significant improvements in outcome measures. This inadequacy may be a consequence of reduced treatment adherence with continuous positive airway pressure (CPAP) or because the effect of CPAP on outcome measures is small or absent in some patients despite adequate adherence. Consequently, innovative therapies that directly impact co-morbidities linked to OSA or that increase CPAP adherence could lead to improved outcome measures. In the recent funding cycle, the investigators established that repeated daily exposure to mild intermittent hypoxia (MIH) coupled with CPAP modifies autonomic nervous system activity and dramatically decreases blood pressure compared to CPAP treatment alone. Because MIH was coupled with CPAP, the independent effect of MIH on blood pressure was not established. Moreover, it was not established if these outcomes were sustained for a prolonged time period (i.e. weeks to months).
Although the investigators obtained some indirect evidence that modifications in autonomic nervous system activity were coupled to the reduction in blood pressure, the investigators did not establish if modifications in microvascular function were evident. Microvascular dysfunction together with sympatho-vagal imbalance may have consequences not only for peripheral vascular resistance and blood pressure but also for muscle perfusion and metabolism, thereby limiting exercise performance and increasing fatigability in patients with OSA. Thus, reductions in blood pressure and improvement in microvascular function following treatment with MIH might serve to improve exercise capacity and reverse performance fatigue in individuals with OSA.
Besides its potential effect on autonomic and cardiovascular function, the investigators and others previously established that acute exposure to MIH initiates sustained increases in upper airway muscle activity in humans. This sustained increase is a form of respiratory plasticity known as long-term facilitation. However, in the absence of CPAP the investigators have shown that acute MIH immediately prior to or during sleep leads to increases in apnea severity. This might occur because the manifestation of long-term facilitation is absent in the presence of hypocapnia. Hypocapnia can be induced during sleep by the initiation of another form of plasticity known as progressive augmentation. However, it is possible that the combination of daily exposure to MIH administered many hours before the sleep period may mitigate the effects of progressive augmentation leading to increased upper airway stability.
Independent of this possibility, the investigators showed in the previous funding cycle that increased upper airway stability following treatment with MIH was coupled to a reduction in therapeutic CPAP and improved adherence. However, improved adherence to CPAP might also be linked to an increase in the arousal threshold to both respiratory and non-respiratory stimuli. All the uncertainties outlined above will be addressed in the present proposal.
Study design
- Primary purpose
- Treatment
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, outcomes assessor)
- Number of arms
- 2
- Model description
- The present study utilizes a double blind parallel randomized design using an equal allocation ratio for each arm. Block randomization will be conducted to reduce the probability that a disproportionate number of participants are randomized to one group. Mild intermittent hypoxia and "sham MIH" will be administered during wakefulness each day for 15 days over a 3-week period.
| Arm | Type | Receives |
|---|---|---|
| Mild Intermittent Hypoxia (MIH) | Experimental | Other: Mild Intermittent HypoxiaThis arm of the protocol will receive mild intermittent hypoxia (8% oxygen) with end-tidal carbon dioxide maintained 2 millimeters of mercury above baseline, while in the laboratory. |
| Sham Mild Intermittent Hypoxia (Sham MIH) | Sham comparator | Other: Sham MIHThis arm of the protocol will receive sham MIH (the equivalent of room air), while in the laboratory. |
Who may qualify
- Ages
- 30 to 60 years
- Sex
- All
- Healthy volunteers
- Not accepted
- Age groups
- Adult
Key inclusion criteria (6 listed)
- Male or female of any race, 30-60 years of age with a BMI of less than 40 kg/m2 and a weight to hip ratio of less than 1.3in males and 1.2 in females along with pure or predominantly (i.e., comprised of both a central and obstructive component)OSA (AHI less than or equal to 100 events per hour and an average oxygen desaturation level of 85 % or greater).
- Participants will be newly diagnosed and not previously treated with CPAP.
- Participants will also be diagnosed with hypertension. Participants will either be untreated or will be treated unsuccessfully with a single prescribed medication for hypertension. Hypertension will be classified according to the American Heart Association 2018 criteria which includes an elevated systolic blood pressure in the range of 120-129 and a diastolic pressure less than 80 mmHg in addition to stage I and stage II hypertension defined by a systolic blood pressure greater than 130 mmHg and a diastolic pressure greater than 80 mmHg.
- Participants will also be included if they are pre-diabetic (HbA1C: 5.7 - 6.4 %; fasting blood glucose: 100 - 125 mg/dL) and have cholesterol levels ranging from 200-239 mg/dL.
- All participants will have normal lung function and a normal EKG with no or minimal alcohol consumption (< 2 oz of alcohol/night).
Key exclusion criteria (6 listed)
- Participants with baseline blood pressure greater than 160/110 will be excluded from participation.
- Participants on any medications, with the exception of a single prescribed medication for individuals with resistant hypertension.
- Participants with any other known disease (e.g. pulmonary hypertension).
- Participants using any sleep promoting supplements including melatonin.
- Night shift workers or participants who recently travelled across time zones.
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Mild Intermittent HypoxiaThe MIH protocol will be comprised of a 20-minute baseline period followed by exposure to twelve two-minute episodes of hypoxia [partial pressure of end-tidal oxygen (PETO2)= 50 mmHg]. Each episode will be interspersed with a 2-minute recovery period under normoxic conditions. The final episode will be followed by a 30-minute end-recovery period. The partial pressure of end-tidal carbon dioxide (PETCO2) will be sustained 2 mmHg above baseline values for the last ten minutes of baseline and throughout the remainder of the protocol. To rapidly induce a PETO2 of 50 mmHg participants will inspire a gas mixture comprised of 8 % oxygen and 92 % nitrogen from a non-diffusible bag. To maintain PETO2 (i.e. 50 mmHg) and PETCO2 (i.e. 2 mmHg above baseline) at the desired levels supplemental oxygen and carbon dioxide will be added to the inspiratory line from the output of a flow meter device that receives inputs from tanks of 100 % oxygen and 100 % carbon dioxide. | Other | Mild Intermittent Hypoxia (MIH) |
| Sham MIHDuring "sham MIH" the participants will be exposed to compressed air (the equivalent of room air). | Other | Sham Mild Intermittent Hypoxia (Sham MIH) |
Primary outcome
Change in Blood Pressure
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Blood pressure measures over 24 hours will be obtained. Blood pressure will be measured every 20 minutes beginning on Sunday at 6 AM and ending Monday at 6 AM. Participants will wear an actigraph (Actiwatch Spectrum, Respironics) and record their activities in a journal to determine the arousal state (i.e., active wakefulness, quiet wakefulness and sleep) associated with each blood pressure measurement. The data will be separated into active-awake, rest-awake and sleep based on the activity log and corresponding data from an actigraph watch. The average value of blood pressure in a healthy individual is 120/80 mmHg. In their participants with OSA, the investigators expect the blood pressure to be higher at baseline and decrease 15 days after treatment. The investigators also expect that this reduction will be maintained at 4 and 8-weeks following treatment.
Change in Microvascular Function (Maximal hyperemic Response)
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Microvascular reactivity associated with hyperemia induced by vascular occlusion will be determined by analyzing the maximal hyperemic response (MHR) of tissue saturation index (TSI) signal derived from near-infrared spectroscopy (NIRS) of the lateral gastrocnemius muscle of the non-dominant leg. The average value of TSI MHR of the NIRS signals in healthy individuals is 159±9 %. In their participants with OSA, the investigators expect these values to be lower at baseline and to increase 15 days after treatment. The investigators also expect that the increase will be maintained 4 and 8-weeks following treatment.
Change in Microvascular Function (Time to reach Maximal Hyperemic Response)
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Microvascular reactivity associated with hyperemia induced by vascular occlusion will be determined by analyzing the time to reach maximal hyperemic response (tM) of tissue saturation index (TSI) signal derived from near-infrared spectroscopy (NIRS) of the lateral gastrocnemius muscle of the non-dominant leg. The average value of tM TSI in healthy individuals is 39±5 s. In their participants with OSA, the investigators expect these values to be higher at baseline and to lower 15 days after treatment. The investigators also expect that the decrease will be maintained 4 and 8-weeks following treatment.
7 secondary outcomes
Change in Muscle Oxygen Extraction (Time Delay)
Time frame: Change at 15 days following treatment compared to baseline
Change in Muscle Oxygen Extraction (Mean Response Time)
Time frame: Change at 15 days following treatment compared to baseline
Change in Sympatho-Vagal Balance (Blood Pressure Variability)
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Muscle Oxygen Extraction (Tau)
Time frame: Change at 15 days following treatment compared to baseline
Change in Maximal Oxygen Consumption
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Fatigability
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Change in Sympatho-Vagal Balance (Heart Rate Variability)
Time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 4 Dec 2025.
- Individual participant dataSharing planned: No
Related trials for Obstructive Sleep Apnea
RecruitingObservational study
Development and Validation of a Multimodal Deep Learning Model Using Peripheral Oxygen Saturation and Ballistocardiography Signals for Predicting Apnea-Hypopnea Index in Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 3
A Study to Learn About the Monthly Dosing Study Medicine Called Berobenatide in Adults With Breathing Problems During Sleep and Overweight or Obesity Who Do Not Use a Breathing Machine (PAP) (VESPER-OSA 2)
Apnea, Sleep Disorders
Not yet recruitingPhase 2
Supplemental Oxygen for Sleep-Disordered Breathing in Adults With Chronic Opioid Use.
Sleep-disordered Breathing, Chronic Opioid Use
Recruiting
Nightly Wearable Monitoring During Home-Based Submental Electrical Stimulation for Obstructive Sleep Apnea
Obstructive Sleep Apnea
RecruitingPhase 1/2
DRonabinol Treatment of OSA
Obstructive Sleep Apnea
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Jason H Mateika, PhD MS BS principal investigator
John D. Dingell VA Medical Center, Detroit, MI
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A Phase 1/2 study testing Mild Intermittent Hypoxia in people with Obstructive Sleep Apnea, run by VA Office of Research and Development at 1 site in United States.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 6 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: looking for participants now, as of the sponsor's last update on 4 Dec 2025. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
What does this combined phase mean?
Phase 1 studies test a treatment in a small group of people for the first time or in a new way, mainly to check safety and find the right dose.
Phase 2 studies give the treatment to a larger group to see whether it has the intended effect and to keep checking safety.
Not every study follows the same path, and some studies (observational studies, device studies) have no phase.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Jason H Mateika, PhD MS BS ((313) 576-4481 ext. 64481, jmateika@med.wayne.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Change in Blood Pressure (time frame: Change at 15 days, 4 and 8- weeks following treatment compared to baseline). The study lists 3 primary outcomes in all. It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 4 Dec 2025.